NFL Player to Shave Beard for Cancer Research
"Former Michigan State football star T.J. Duckett has been busy in the mid-Michigan area doing work for a number of area charities.
Helping to fight cancer is one of his biggest and most personal causes.
Duckett will shave off his prominent and ever-growing facial hair next March as part of the annual St. Baldrick's Foundation's children's cancer research fundraiser.
"People call me (MMA fighter) Kimbo Slice. But when we tell people why I'm doing it, it really opens people's eyes to it," Duckett said. "That brings awareness to the cause and that's half the battle."
Duckett lost his mother to non-Hodgkin's lymphoma in 2000 after a six-year battle."
Read More: http://www.lansingstatejournal.com/apps/pbcs.dll/article?AID=201010260330
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
